Howe & Rusling’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Howe & Rusling’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,000	Closed	-$3K	–	1126
2022 Q3	$3K	Sell	2,000 -200	-9%	-$454	﹤0.01%	830
2022 Q2	$4K	Buy	2,200 +200	+10%	+$346	﹤0.01%	746
2022 Q1	$5K	Buy	2,000 +1,000	+100%	+$3.12K	﹤0.01%	683
2021 Q4	$5K	Hold	1,000	–	–	﹤0.01%	699
2021 Q3	$8K	Hold	1,000	–	–	﹤0.01%	556
2021 Q2	$10K	Hold	1,000	–	–	﹤0.01%	503
2021 Q1	$8K	Hold	1,000	–	–	﹤0.01%	537
2020 Q4	$7K	Hold	1,000	–	–	﹤0.01%	556
2020 Q3	$11K	Buy	+1,000	New	+$9.15K	﹤0.01%	434

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BRF

B. Riley Financial Los Angeles, California $434M AUM 751.56% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Howe & Rusling's SRNE Position: Q4 2022 in Review

Howe & Rusling sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 2,000 shares — an estimated $3K sold.

Howe & Rusling first reported a position in SRNE in Q3 2020 and held it in 9 quarters. The position peaked at $11K in Q3 2020. 221 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

Howe & Rusling reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Howe & Rusling sold 2,000 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $3K.
Howe & Rusling first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 9 quarters.
Howe & Rusling's Sorrento Therapeutics, Inc. position peaked at $11K in Q3 2020.
221 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.